DWP708

· Daewoong Pharmaceutical Co. LTD.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for DWP708, covering 2024-04-04 to 2024-04-04. Get the full timeline:

Most recent: Clinical Trial Update: DWP708 for Treating Epidermal Growth Factor Receptor Inhibitor Related Skin Toxicities [Phase 2]